Bifosfonatos (BF)Se trata de fármacos con potentes propiedades antiresortivasque han demostrado una contrastada eficaciaen la prevención de fracturas osteoporóticas tanto enmujeres postmenopáusicas (83-87) como en el tratamientode la OP asociada a GC (88-95) .Este grupo terapéutico incluye el etidronato, pamidronato,tiludronato, <strong>al</strong>endronato, risedronato e inbandronato.Todos ellos han demostrado ser superiores aplacebo en la prevención de fracturas tanto vertebr<strong>al</strong>es,como de cuello de fémur, en estudios metodológicamentebien diseñados (82-95) . Pocos estudios han ev<strong>al</strong>uadola eficacia de los BF en el manejo de la OP asociadaa la <strong>EII</strong> (96,99) (Tabla V). En un estudio, <strong>al</strong>eatorizado,controlado y doble ciego, el <strong>al</strong>endronato a la dosis de10 mg/día consiguió incrementar la masa ósea en column<strong>al</strong>umbar en 32 pacientes con EC (4,6% ± 1,2% versusun descenso de 0,9% ± 1% en el grupo de placebo[p< 0.01]) (96) . Resultados similares se han obtenido conrisedronato (97) y con pamidronato (98,99) proporcionandoevidencias de su efectividad en la prevención de la PMOen los pacientes.La absorción intestin<strong>al</strong> de los BF administrados por víaor<strong>al</strong> es baja (< 5%) y su biodisponibilidad podría estarcomprometida en pacientes con <strong>EII</strong> activa o que han sidosometidos a amplias resecciones de intestino delgado.En t<strong>al</strong>es casos, la administración de pamidronato por víai.v. constituye una buena <strong>al</strong>ternativa (30 mg cada 3 mesesasociados a 1.000 mg de c<strong>al</strong>cio y 400 UI de vitaminaD diarios) (98-99) .Otras terapias (estrógenos y PTH)EstrógenosEl r<strong>al</strong>oxifeno ha sido aprobado para la prevención de laOP en mujeres menopáusicas. Aunque no existen estudiosdiseñados para pacientes con <strong>EII</strong>, su eficacia ha sidocomprobada en metaanálisis que demuestran una reduccióndel riesgo de fracturas vertebr<strong>al</strong>es de un 40%con dosis de 60 mg/día (100).TeriparatideSe trata de un fragmento de PTH humana obtenido poringeniería genética capaz de estimular la formación dehueso. Su administración a la dosis de 20 y 40 microgramosdiarios por vía subcutánea durante 18 meses hademostrado reducir el riesgo de fracturas en mujerespostmenopáusicas (101) y en hombres con OP secundariaa hipogonadismo (102) . Algunos autores preconizan su empleoen grupos seleccionados de enfermos que requierentratamiento con corticoesteroides a largo plazo (103) .BIBLIOGRAFÍA1. Scott EM Gaywood BB. Guidelines for osteoporosis in coeliac disease andinflammatory bowel disease, Gut 2000; 46 (Suppl I):i1-i8.2. Bernstein CN, Leslie WD, Lebof M.S. AGA technic<strong>al</strong> review: Osteoporosisin gastrointestin<strong>al</strong> diseases. Gastroenterology 2003; 124:795-807.3. American Gastroenterologic<strong>al</strong> Association medic<strong>al</strong> position statement:Guidelines on osteoporosis in gastrointestin<strong>al</strong> diseases. Gastroenterology2003; 124:791-4.4. Manolagas, SC, Jilka, RL. Bone marrow, cytokines, and bone remodeling:emerging insights into the pathophysiology of osteoporosis. N Engl J Med1995; 332:305-11.5. World He<strong>al</strong>th Organisation. Assesment of fracture risk and its applicationto postmenopaus<strong>al</strong> osteoporosis. World He<strong>al</strong>th Organ Tech Rep 1994: SerNo 843.6. Genant HK, M<strong>al</strong>l JC, Wagonfeld JB, Horst JV, Lanzi LH. Skelet<strong>al</strong> deminer<strong>al</strong>izationand growth retardation in inflammatory bowel disease. InvestRadiol. 1976;11:541-9.7. Compston JE, Judd D, Crawley EO, Evans WD, Evans C,Church HA,et <strong>al</strong>.Osteoporosis in patients with inflammatory bowel disease. Gut 1987;28:410.-5.8. Motley RJ, Crawley EO, Evans C, Rhodes J, Compston JE. Increased rateof spin<strong>al</strong> trabecular bone loss in patients with inflammatory bowel disease.Scand J Gastroenterol 1992; 27: 1332-6.9. Clements D, Motley Rj, Evans WD, Harries AD, Rodhes J, Coles RJ, et <strong>al</strong>.Longitudin<strong>al</strong> study of cortic<strong>al</strong> bone loss in patients with inflammatory boweldisease. Scand J Gastroenterol 1992; 27: 1055-60.10. Silvennoinen JA, Karttunen TJ, Niemela SE,Manelius JJ, Lehtola JR,. A controlledstudy of bone miner<strong>al</strong> density in patients with inflammatory boweldisease. Gut 1995; 37:71.-6.10b. Martínez N, López-Rodríguez F, Mezquita-Raya P, Muñoz-Torres M, GonzálezJ: Factores relacionados con la pérdida de masa ósea en pacientesdiagnosticados de enfermedad inflamatoria intestin<strong>al</strong>. Endocrinología2001, 48 (Supl. 2):45-46.11. Pigot F, Roux C, Chaussade S, Hardelin D, Pelleter O, Du Puy Montbrun,et <strong>al</strong>. Low bone miner<strong>al</strong> density in patients with inflammatory bowel disease.Dig Dis Sci 1992; 37: 1396-1403.12. Staun M, Tjellesen L, Th<strong>al</strong>e M . Bone miner<strong>al</strong> density in patients withCrohn´s disease. Scand J Gastroenterol 1998; 93: 1483-90.13. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I,Moniz C,. Reduced bone density in patients with inflammatory bowel disease.Gut 1997; 40: 228-33.14. Driscoll RH, Meredith SC, Strin M, Rosenberg IH. Vitamin D deficiency andbone disease in patients with Cronh´s disease. Gastroenterology 1982;83: 1252-8.15. Pollack RD, Karmelli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D.Femor<strong>al</strong> neck osteopenia in patients with inflammatory bowel disease.Am J Gastroenterol 1998; 93: 1483-90.16. Schoon EJ, van Nunen AB, Wouters RS, Stockbrügger RW, Russel MG. Osteopeniaand osteoporosis in Crohn’s disease: prev<strong>al</strong>ence in a Dutch population-basedcohort. Scand J Gastroenterol 2000; 35:43-7.17. Jahnsen, J, F<strong>al</strong>ch, JA, Aadland, E, Mowinckel, P. Bone miner<strong>al</strong> density isreduced in patients with Crohn’s disease but not in patients with ulcerativecolitis: a population based study. Gut 1997; 40:313-9.18. Robinson RJ, <strong>al</strong>-Azzawi F, Iqb<strong>al</strong> SJ, Abrams K, Mayberry JF. The relation ofhand skin-fold thickness to bone miner<strong>al</strong> density in patients with Crohn’sdisease. Eur J Gastroenterol Hepatol 1997;9:945-9.19. Schulte, C, Dignass, AU, Mann, K, Goebell, H. Reduced bone miner<strong>al</strong> den-192 • Enfermedad Inflamatoria Intestin<strong>al</strong> <strong>al</strong> día - Vol. 7 - Nº. 2 - 2008
Enfermedades asociadassity and unb<strong>al</strong>anced bone metabolism in patients with inflammatory boweldisease. Inflamm Bowel Dis 1998; 4:268-75.20. Boot AM, Bouquet J, Krenning EP, de Munick Keizer-Schrama SMPF. Boneminer<strong>al</strong> density and nutrition<strong>al</strong> status in children with chronic inflammatorybowel disease. Gut 1998; 42; 188-94.21. Gokh<strong>al</strong>e R, Favous MJ, Karrison T, Sutton MM, Rich B, Kirschner BS. Boneminer<strong>al</strong> density and nutrition<strong>al</strong> status in children with chronic inflammatorybowel disease. Gastroenterology 1998; 114; 902-11.22. Motley RJ, Clements D, Evans WD,Crawley EO, Evans C, Rhodes J, et <strong>al</strong>.A four year longitudin<strong>al</strong> study of bone loss in patients with inflammatorybowel disease. Bone Miner 1993 1993; 23: 95-104.23. Ghost S, Cowen S, Hannan WJ, Ferguson A. Low bone miner<strong>al</strong> density inCrohn´s disease, but not in ulcerative colitis, at diagnosis. Gastroenterology,1994: 107: 1031-9.24. Jahnsen J, F<strong>al</strong>ch JA, Asdliand E, Mowinckel P. Bone miner<strong>al</strong> density is reducedin patients with Crohn´s disease but not in ulcerative colitis: a populationbased study. Gut 1997; 40: 313-925. Ulivieri FM, Liscindriano D, Ranzi T,Taioli E, Cermesoni L, Piodi LP, et <strong>al</strong>.Bone miner<strong>al</strong> density and body composition in patients with ulcerativecolitis : Am J Gastroenterol 2000 ; 95 : 1491-4.26. Lee SH, Kim HJ, Yang SK, Kim WH, Joo YS, Dong SH, et <strong>al</strong>. Decreased trabecularbone miner<strong>al</strong> density in newly diagnosed inflammatory bowel diseasepatients in Korea. J Gastroenterol Hepatol 2000;15:512-8.27. Roux C, Abitbol C, Chaussade S, Kolta S, Guillemant S, Dougados M, et<strong>al</strong>. Bone loss in patients with inflammatory disease ; a prospective study.Osteoporos int 1995:5:156-60.28. Dinca M, Fries W, Luisetto G, Peccolo F,Bottega F, Leone L, et <strong>al</strong>. Evolutionof osteopenia in inflammatory bowel disease. Am J Gastroenterol1999; 94:1292.-7.29. Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi Porro G.Altered bone metabolism in inflammatory bowel disease: there is a differencebetween Crohn’s disease and ulcerative colitis. J Intern Med 2000;247:63-70.30. Robinson RJ, <strong>al</strong>-Azzawi, F, Iqb<strong>al</strong> SJ, Kryswchi T, Almond L, Abrams K, et<strong>al</strong>. Osteoporosis and determinants of bone density in patients with Crohn’sdisease. Dig Dis Sci 1998; 43:2500-6.31. Schoon EJ, van Nunen AB, Wouters, RS, Stockbrügger RW, Russel MG.Osteopenia and osteoporosis in Crohn’s disease: prev<strong>al</strong>ence in a Dutchpopulation-based cohort. Scand J Gastroenterol 2000; 35:43-7.32. Andreassen H, Hylander E, Rix M. Gender, age, and body weight are themajor predictive factors forbone miner<strong>al</strong> density in Crohn’s disease: a casecontrolcross-section<strong>al</strong> study of 113 patients. Am J Gastroenterol 1999;94:824-8.33. Dresner-Pollak, R, Karmeli F, Eliakim R, Ackerman Z,Rachmilewitz D. Increasedurinary N-telopeptide cross-linked type 1 collagen predicts boneloss in patients with inflammatory bowel disease. Am J Gastroenterol2000; 95:699-704.34. Abitbol V, Roux C, Guillemant S, V<strong>al</strong>leur P,Hautefeuille P, Dougados M, et,<strong>al</strong>. Bone assessment in patients with ile<strong>al</strong> pouch-an<strong>al</strong> anastomosis for inflammatorybowel disease. Br J Surg 1997; 84:1551-4.35. Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, CouturierD et <strong>al</strong>. Metabolic bone assessment in patients with inflammatorybowel disease. Gastroenterology 1995; 108:417-22.36. Fries W, Dinca M, Luisetto G, Peccolo F, Bottega F, Martin A, et <strong>al</strong>. C<strong>al</strong>cane<strong>al</strong>ultrasound bone densitometry in inflammatory bowel disease—acomparison withdouble x-ray densitometry of the lumbar spine. Am J Gastroenterol1998; 93:2339-44.37. Staun M, Tjellesen L, Th<strong>al</strong>e M, Schaadt O, Jarnum S. Bone miner<strong>al</strong> contentin patients with Crohn’s disease. A longitudin<strong>al</strong> study in patients withbowel resections. Scand J Gastroenterol 1997; 32:226-32.38. Floren CH, Ahren B, Bengtsson M, Bartosik J, Obrant K,et <strong>al</strong>. Bone miner<strong>al</strong>density inpatients with Crohn’s disease during long-term treatmentwith azathioprine. J Intern Med 1998; 243:123-6.39. Semeao EJ, St<strong>al</strong>lings VA, Peck SN, Piccoli DA. Vertebr<strong>al</strong> compression fracturesin pediatric patients with Crohn’s disease. Gastroenterology 1997;112:1710-3.40. Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture riskis increased in Crohn’s disease, but not in ulcerative colitis. Gut 2000;46:176-81.41. Vestergaard, P, Mosekilde, L. Fracture risk in patients with celiac disease,Crohn’s disease, and ulcerative colitis: a nationwide follow-up study of16,416 patients in Denmark. Am J Epidemiol 2002; 156:1-10.42. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence offracture among patients with inflammatory bowel disease. A populationbasedcohort study. Ann Intern Med 2000; 133:795-9.43. Loftus EV Jr, Crowson CS, Sandborn WJ,Tremaine WJ, O´f<strong>al</strong>lon WM, MeltonLJ 3rd. Long-term fracture risk in patients with Crohn’s disease: A population-basedstudy in Olmsted County, Minnesota. Gastroenterology2002;123:468-75.44. Klaus J, Armbrecht, G, Steinkamp, M, Brückel J, Rieber A, Adler G, et <strong>al</strong>:Prev<strong>al</strong>ence of osteoporotic vertebr<strong>al</strong> fractures in patients with Crohn’s disease.Gut 2002; 51:654-8.45. Stockbrugger RW, Schoon EJ, Bollani S, Mills PR, Israeli E, Landgraf L, et<strong>al</strong>. Discordance between the degree of osteopenia and the prev<strong>al</strong>ence ofspontaneous vertebr<strong>al</strong> fractures in Crohn’s disease. Aliment PharmacolTher 2002; 16:1519-27.46. Xiong DH, Lei SF, Yang F, Wang L, Peng YM, Wang W et <strong>al</strong>. Low-densitylipoprotein receptor-related protein 5 (LRP5) gene polymorphims are associatedwith mass in both Chinese and whites. J Bone Miner Res 2007;22: 385-93.47. Ezura Y, Nakajima T, Urano T, Sudo Y, Kajita M, Yoshida H et <strong>al</strong>. Associationof a single-nucleotide variation (A1330V) in the low-density lipoproteinreceptor-related protein 5 gene (LRP5) with bone miner<strong>al</strong> density inadult Japanese women. Bone 2007;40:997-1005.48. Saarinen A, V<strong>al</strong>imaki VV, V<strong>al</strong>imaki MJ, Loyttyniemi E, Auro K, Uusen P et<strong>al</strong>. The A1330V polymorphism of the low-density lipoprotein receptor-relatedprotein 5 gene (LRP5) associates with low peak bone mass in younghe<strong>al</strong>thy men. Bone 2007;1006-12.49. Rodriguez-Bores L, Barahona-Garrido J, Yamamoto J.K.. Basic and clinic<strong>al</strong>aspects of osteoporosis in inflammatory bowel disease. World J Gastroenterol2007;13:6156-65.50. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1 <strong>al</strong>pha 25-DihidroxyvitaminD3 binding macromolecules in human B lymphocytes: effectson inmunoglobulin production. J Inmunol 1986;136;2734-40.51. Manolagas Sc. The role of IL-6 type cyrokines and their receptors in bone.Ann N Y Acad Sci 1998; 840:194-204.52. Montenegro Sergio D, Pedroza Nuñez I.J., Vargas Eced S. Ramos M.H.Metabolismo óseo. Actu<strong>al</strong>ización. Revista de Posgrado de la VIa Cátedrade Medicina. 2002;117:18-21.53. Kong YY, Penninger JM. Molecular control of bone remodeling and osteoporosis.Exp Gerontol 2000;35: 1047-56.54. Shoum<strong>al</strong> M, Kolarz G, Haberhauer G, Woloszcuk W, Hawa G, Kingler A.Osteoprotegerin and the receptor activator of NF-Kappa B ligand in theserum and synovi<strong>al</strong> fluid. A comparison of patients with longstandingrheumatoid arthritis and osteoarthritis. Rheumatol Int 2005; 26: 63-9.55. Shoum<strong>al</strong> M, Kolarz G, Woloszcuk W, Hawa G, Kingler A. Serum Osteo-193 • Enfermedad Inflamatoria Intestin<strong>al</strong> <strong>al</strong> día - Vol. 7 - Nº. 2 - 2008